Central Nervous System News and Research

RSS

Cause of multiple sclerosis: Researchers test autoimmune hypothesis

A non-pathogenic bacterium is capable to trigger an autoimmune disease similar to the multiple sclerosis in the mouse, the model animal which helps to explain how human diseases work. This is what a group of researchers from the Catholic University of Rome, led by Francesco Ria (Institute of General Pathology) and Giovanni Delogu (Institute of Microbiology), have explained for the first time in a recently published article on the Journal of Immunology.

26 Feb 2010

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

IOS Press is pleased to announce the 20th anniversary of the peer-reviewed journal Restorative Neurology and Neuroscience. Since founded in 1989 by pioneering neuroscientist Donald G. Stein, RNN has focused on the emerging field of brain plasticity, repair and rehabilitation and has published not only numerous original scientific publications, but also review papers in basic research (animal experiments, in vitro studies) and in the clinical sciences.

25 Feb 2010

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in the Feb. 24 issue of the Journal of Neuroscience.

25 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

SRI International establishes new Neurodegenerative Diseases Research Program

SRI International, an independent nonprofit research and development institute, announced today that a new Neurodegenerative Diseases Research Program has been established within its Center for Health Sciences. This new SRI group of neuroscientists and researchers working at the cutting edge of science brings $6.2 million of funding from the National Institutes of Health (NIH), including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Environmental Health Sciences (NIEHS), and National Institute of General Medical Sciences (NIGMS).

19 Feb 2010

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows.

18 Feb 2010

Anulex Technologies announces the commercial availability of Xclose Plus Tissue Repair System

Anulex Technologies, Inc., a privately held medical device manufacturer focusing on spinal disc Preservation & Anular Repair™ products, announced the commercial availability of the Xclose™ Plus Tissue Repair System at the AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves meeting in Orlando, Florida.

18 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Alkermes, Inc. today announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

16 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that it has hired MTS Health Partners, L.P. as strategic advisor to complement and augment the company’s ongoing business development activities.

12 Feb 2010

Medicare payment cuts may impact patients’ access to quality neurosurgical care

As lawmakers continue to wrestle with how best to reform the Medicare physician payment system, the results of a new survey by the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the Council of State Neurosurgical Societies (CSNS) paint a troubling picture for patients if drastic Medicare physician payment cuts continue.

11 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.

10 Feb 2010

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

In an aging society, falling is a growing problem. Just one bad fall can mark the start of a downward spiral in an older person's health and quality of life. The cost of treating falls also puts a heavy burden on the health care system. Toronto Rehab scientists have developed a simple footwear insole called SoleSensor(TM), which has proven to improve balance and prevent falls.

10 Feb 2010

APA releases proposed draft diagnostic criteria for DSM-5

The American Psychiatric Association today released the proposed draft diagnostic criteria for the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM). The draft criteria represent content changes under consideration for DSM, which is the standard classification of mental disorders used by mental health and other health professionals, and is used for diagnostic and research purposes.

10 Feb 2010

TI commences Phase IIa clinical trial for its lead molecule in CDH

Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.

10 Feb 2010

Central Nervous System News and Research

Cause of multiple sclerosis: Researchers test autoimmune hypothesis

Biovail reports 33% increase in total revenues for fourth-quarter 2009

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

SRI International establishes new Neurodegenerative Diseases Research Program

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Anulex Technologies announces the commercial availability of Xclose Plus Tissue Repair System

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Meda publishes 2009 year-end report

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Medicare payment cuts may impact patients’ access to quality neurosurgical care

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

APA releases proposed draft diagnostic criteria for DSM-5

TI commences Phase IIa clinical trial for its lead molecule in CDH

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News